L
0.599
0.04 (7.38%)
| 前收盘价格 | 0.558 |
| 收盘价格 | 0.545 |
| 成交量 | 873,919 |
| 平均成交量 (3个月) | 6,557,378 |
| 市值 | 9,670,549 |
| 价格/销量 (P/S) | 8.73 |
| 股市价格/股市净资产 (P/B) | 20.43 |
| 52周波幅 | |
| 利润日期 | 11 Aug 2025 - 15 Aug 2025 |
| 营业利益率 (TTM) | -1,304.44% |
| 稀释每股收益 (EPS TTM) | -2.34 |
| 总债务/股东权益 (D/E MRQ) | 64.25% |
| 流动比率 (MRQ) | 0.960 |
| 营业现金流 (OCF TTM) | -15.17 M |
| 杠杆自由现金流 (LFCF TTM) | -11.89 M |
| 资产报酬率 (ROA TTM) | -144.37% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | SeaStar Medical Holding Corpora | 混合的 | 混合的 |
AIStockmoo 评分
-0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.50 |
|
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 1.06% |
| 机构持股比例 | 5.59% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tyche Wealth Partners Llc | 31 Mar 2025 | 37,700 |
| Trinity Financial Advisors Llc | 30 Jun 2025 | 15,000 |
| Great Valley Advisor Group, Inc. | 31 Mar 2025 | 10,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合